Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.

Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, Bardeesy N, Sun H, Williams N, Minna JD, Brekken RA.

Cancer Res. 2010 Apr 1;70(7):2852-61. doi: 10.1158/0008-5472.CAN-09-3892. Epub 2010 Mar 23.

2.

Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.

Awasthi N, Kirane A, Schwarz MA, Toombs JE, Brekken RA, Schwarz RE.

BMC Cancer. 2011 Jan 12;11:15. doi: 10.1186/1471-2407-11-15.

3.

SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.

Greer RM, Peyton M, Larsen JE, Girard L, Xie Y, Gazdar AF, Harran P, Wang L, Brekken RA, Wang X, Minna JD.

Cancer Res. 2011 Dec 15;71(24):7640-8. doi: 10.1158/0008-5472.CAN-10-3947. Epub 2011 Nov 2.

4.

Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.

Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Möller P, Gschwend JE, Simmet T, Debatin KM, Fulda S.

Cancer Res. 2009 Mar 15;69(6):2425-34. doi: 10.1158/0008-5472.CAN-08-2436. Epub 2009 Mar 3.

5.

Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway.

Sun Q, Zheng X, Zhang L, Yu J.

Clin Cancer Res. 2011 Apr 15;17(8):2361-72. doi: 10.1158/1078-0432.CCR-10-2262. Epub 2011 Jan 17.

6.

Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.

Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM, Fulda S.

Cancer Res. 2008 Oct 1;68(19):7956-65. doi: 10.1158/0008-5472.CAN-08-1296.

7.

The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.

Jung DB, Yun M, Kim EO, Kim J, Kim B, Jung JH, Wang E, Mukhopadhyay D, Hammond E, Dredge K, Shridhar V, Kim SH.

Oncotarget. 2015 Mar 10;6(7):4992-5004.

8.

Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.

Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, Toyoda E, Kawaguchi Y, Uemoto S.

J Surg Res. 2007 Oct;142(2):281-6. Epub 2007 Jul 19.

PMID:
17640673
9.

Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.

Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM.

Cancer Biol Ther. 2010 Nov 1;10(9):885-92. doi: 10.4161/cbt.10.9.13237. Epub 2010 Nov 1.

10.

Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.

Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, Welsh K, Reed JC, Armour EP, Wong J, Herman J, Rakheja D, Maitra A.

Mol Cancer Ther. 2007 Mar;6(3):957-66. Epub 2007 Mar 5.

11.

BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2012 Dec;11(12):2644-53. doi: 10.1158/1535-7163.MCT-12-0447. Epub 2012 Oct 9.

12.

Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.

Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman JW.

Mol Cancer. 2013 Sep 11;12(1):104. doi: 10.1186/1476-4598-12-104.

13.

Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.

Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK.

Cancer Res. 2007 Oct 15;67(20):9903-12.

14.

Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.

Wang ZH, Chen H, Guo HC, Tong HF, Liu JX, Wei WT, Tan W, Ni ZL, Liu HB, Lin SZ.

Int J Oncol. 2011 Nov;39(5):1123-31. doi: 10.3892/ijo.2011.1115. Epub 2011 Jul 6.

PMID:
21743963
15.

Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.

Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV.

Cancer Lett. 2013 Jul 10;335(1):41-51. doi: 10.1016/j.canlet.2013.01.054. Epub 2013 Feb 10.

16.

Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.

Wu MS, Wang GF, Zhao ZQ, Liang Y, Wang HB, Wu MY, Min P, Chen LZ, Feng QS, Bei JX, Zeng YX, Yang D.

Mol Cancer Ther. 2013 Sep;12(9):1728-37. doi: 10.1158/1535-7163.MCT-13-0017. Epub 2013 May 22.

17.

Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.

Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.

Gastroenterology. 2015 Dec;149(7):1932-1943.e9. doi: 10.1053/j.gastro.2015.07.058. Epub 2015 Aug 7.

PMID:
26255562
19.

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.

Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR.

Breast Cancer Res Treat. 2013 Jan;137(2):359-71. doi: 10.1007/s10549-012-2352-6. Epub 2012 Dec 7.

PMID:
23225169
20.

A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.

Kawanami T, Takiguchi S, Ikeda N, Funakoshi A.

Oncol Rep. 2012 Mar;27(3):867-72. doi: 10.3892/or.2011.1597. Epub 2011 Dec 20.

PMID:
22200743
Items per page

Supplemental Content

Write to the Help Desk